Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Appearance
Content deleted Content added
Add #WHO-EM marks |
added Danuglipron |
||
Line 107: | Line 107: | ||
| list2 = |
| list2 = |
||
*[[Albiglutide]]<sup>‡</sup> |
*[[Albiglutide]]<sup>‡</sup> |
||
*[[Danuglipron]] |
|||
*[[Dulaglutide]] |
*[[Dulaglutide]] |
||
*[[Exenatide]] |
*[[Exenatide]] |
Revision as of 14:09, 24 May 2023
This template's initial visibility currently defaults to autocollapse
, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state=
parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}
will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}
will show the template expanded, i.e. fully visible.